Literature DB >> 19040301

The mid-range of the adjusted level of ferritin can predict the chronic course in patients with adult onset Still's disease.

Sang-Won Lee1, Yong-Beom Park, Jung-Soo Song, Soo-Kon Lee.   

Abstract

OBJECTIVE: To find a measure that can predict the disease course in patients with adult onset Still's disease (AOSD).
METHODS: We retrospectively investigated the medical records of 71 hospitalized patients with AOSD. Patients were divided according to chronic and nonchronic disease course. The initial laboratory results were defined as those at the time of admission, the extremely deviated laboratory results as the highest or the lowest results, and the adjusted laboratory results as area under the curve divided by the days of hospitalization. All measures were compared and the odds ratio (OR) for the chronic disease pattern was assessed.
RESULTS: The mean age was 39.7+/-13.5 years and women accounted for 63 of the total 71 (88.7%). Thirty patients (42.3%) had self-limited disease, 9 (12.7%) intermittent disease, and 23 (32.4%) the chronic disease pattern (32.4%). Nine patients (12.7%) died. The initial levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ferritin, the highest levels of lactate dehydrogenase (LDH) and ferritin, and the adjusted level of ferritin in patients with chronic disease were significantly higher than those with nonchronic disease. Among them, only the middle range of the adjusted ferritin level (784.1-4120.0 ng/ml) was found to have a significant predictive value for the chronic disease pattern (OR 81.7, p=0.007).
CONCLUSION: A novel measure, the adjusted level of ferritin during the first hospitalization, might be useful to predict progression to chronic disease in patients with AOSD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19040301     DOI: 10.3899/jrheum.080537

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Evaluating the multivisceral involvement on adult-onset Still's disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study.

Authors:  Ilenia Di Cola; Federico Bruno; Onorina Berardicurti; Riccardo Monti; Alessandro Conforti; Alessandra Di Sibio; Viktoriya Pavlych; Carlo Masciocchi; Antonio Barile; Paola Cipriani; Piero Ruscitti
Journal:  Clin Rheumatol       Date:  2021-04-14       Impact factor: 2.980

2.  About the complexity of adult onset Still's disease… and advances still required for its management.

Authors:  Philippe Guilpain; Alain Le Quellec
Journal:  BMC Med       Date:  2017-01-06       Impact factor: 8.775

3.  Red blood cell distribution width is useful in discriminating adult onset Still's disease and sepsis within 24 hours after hospitalization.

Authors:  Hee-Jin Park; Jungsik Song; Yong-Beom Park; Soo-Kon Lee; Sang-Won Lee
Journal:  Korean J Intern Med       Date:  2017-08-25       Impact factor: 2.884

4.  Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Toshiaki Otuki; Ken-Ichi Ueno; Dai Kishida; Yoshiki Sekijima
Journal:  Intern Med       Date:  2019-08-06       Impact factor: 1.271

5.  Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature.

Authors:  Zhong-Bin Han; Ju Wu; Jing Liu; He-Ming Li; Kai Guo; Tong Sun
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

6.  Circulating regulatory T cells in adult-onset Still's disease: Focusing on their plasticity and stability.

Authors:  Yasuhiro Shimojima; Takanori Ichikawa; Dai Kishida; Ryota Takamatsu; Yoshiki Sekijima
Journal:  Clin Exp Immunol       Date:  2021-08-12       Impact factor: 4.330

7.  Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients.

Authors:  Mathieu Gerfaud-Valentin; Delphine Maucort-Boulch; Arnaud Hot; Jean Iwaz; Jacques Ninet; Isabelle Durieu; Christiane Broussolle; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.